36 -4 (90) 2026 - Rasulev Y.E., Abdullaev A.Kh. - NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS

NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS

Rasulev Y.E. - Tashkent State Medical University, "Republican Scientific and Applied Medical Center of Specialized Therapy and Medical Rehabilitation" DM, Republican Scientific and Practical Medical Center for Nephrology and Kidney Transplantation

Abdullaev A.Kh. - Tashkent State Medical University, "Republican Scientific and Applied Medical Center of Specialized Therapy and Medical Rehabilitation" DM

Daminov B.T. - Tashkent State Medical University, Republican Scientific and Practical Medical Center for Nephrology and Kidney Transplantation

Alyavi B.A. - Tashkent State Medical University, "Republican Scientific and Applied Medical Center of Specialized Therapy and Medical Rehabilitation" DM

Usmanova U.Sh. - Tashkent State Medical University, "Republican Scientific and Applied Medical Center of Specialized Therapy and Medical Rehabilitation" DM

Anvarkhodjaeva Sh.G. - Tashkent State Medical University

Razikova K.O. - Tashkent State Medical University

Resume

Over the past two decades, it has become clear that non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NSAIDs) are the leading liver diseases in Western countries. The prevalence of NAFLD has doubled over the past 20 years, while the prevalence of other chronic liver diseases has remained stable or even declined. Recent data suggest that NAFLD and NSAIDs play an equally important role in the Middle East, Far East, Africa, the Caribbean, and Latin America.

Keywords: non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, medicine.

First page

240

Last page

270

For citation:Rasulev Y.E., Abdullaev A.Kh. Daminov B.T. Alyavi B.A. Usmanova U.Sh. Anvarkhodjaeva Sh.G. Razikova K.O. - NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS//New Day in Medicine 4(90)2026 240-270 https://newdayworldmedicine.com/en/new_day_medicine/4-90-2026

List of References

  1. Буеверов А.О., Богомолов П.О., Маевская М.В. Патогенетическое лечение неалкогольного стеатогепатита: обоснование, эффективность, безопасность. Тер арх. 2007;(8):88–92.
  2. Буеверов А.О., Богомолов П.О. Неалкогольная жировая болезнь печени: обоснование патогенетической терапии. Клин персп гастроэнтерол гепатол. 2009;(1):3–9.
  3. Корнеева О.Н., Драпкина О.М., Буеверов А.О., Ивашкин В.Т. Неалкогольная жировая болезнь печени как проявление метаболического синдрома. Клин персп гастроэнтерол гепатол. 2005;(4):21–24.
  4. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395. doi:10.1002/hep.20466
  5. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–967. doi:10.1111/j.1572-0241.2003.07486.x
  6. Ивашкин В.Т., Драпкина О.М., Шульпекова Ю.О. Диагностика и лечение неалкогольной жировой болезни печени (методические рекомендации). М.: М-Вести; 2009. 20 с.
  7. Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности НАЖБП в России (исследование DIREGL 01903). Рос журн гастроэнтерол гепатол колопроктол. 2014;24(4):32–38.
  8. Комова А.Г., Маевская М.В., Ивашкин В.Т. Принципы диагностики диффузных заболеваний печени. Рос журн гастроэнтерол гепатол колопроктол. 2014;24(5):36–41.
  9. Павлов Ч.С., Котович М.М. Биопсия печени в клинической практике. Клиническая медицина. 2007;85(9):72–77.
  10. Павлов Ч.С., Глушенков Д.В., Ивашкин В.Т. Неинвазивная диагностика НАЖБП. Врач. 2010;(12):13–19.

    file

    download